Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artemether + lumefantrine + nevirapine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This represents the concurrent use of artemether-lumefantrine (a fixed-dose antimalarial combination) with nevirapine (an antiretroviral medication). Artemether-lumefantrine is first-line treatment for uncomplicated malaria, while nevirapine is used in HIV therapy. When used together, significant pharmacokinetic interactions occur: nevirapine decreases artemether and dihydroartemisinin exposure but increases lumefantrine exposure. This interaction is clinically relevant for patients requiring treatment for both HIV and malaria.
- Other names
- artemether-lumefantrine + nevirapine
02
Targets
CYP3A4 (Cytochrome P450 3A4)
Beyond the preview
Go deeper on artemether + lumefantrine + nevirapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artemether + lumefantrine + nevirapine.